Johnson & Johnson
NYSE:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
NYSE:JNJ
Watchlist
Price: 151.13 USD 1.02% Market Closed
Market Cap: 364.2B USD
Have any thoughts about
Johnson & Johnson?
Write Note

Johnson & Johnson
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Johnson & Johnson
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Johnson & Johnson
NYSE:JNJ
Operating Income
$23.4B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
1%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Income
$12.9B
CAGR 3-Years
3%
CAGR 5-Years
13%
CAGR 10-Years
14%
Pfizer Inc
NYSE:PFE
Operating Income
$16.9B
CAGR 3-Years
-20%
CAGR 5-Years
14%
CAGR 10-Years
2%
Merck & Co Inc
NYSE:MRK
Operating Income
$21.6B
CAGR 3-Years
6%
CAGR 5-Years
18%
CAGR 10-Years
11%
Zoetis Inc
NYSE:ZTS
Operating Income
$3.4B
CAGR 3-Years
7%
CAGR 5-Years
10%
CAGR 10-Years
13%
Eli Lilly and Co
NYSE:LLY
Operating Income
$19.7B
CAGR 3-Years
33%
CAGR 5-Years
26%
CAGR 10-Years
19%
No Stocks Found

Johnson & Johnson
Glance View

Economic Moat
Wide
Market Cap
363.6B USD
Industry
Pharmaceuticals

Founded in 1886, Johnson & Johnson began its journey with a commitment to revolutionizing healthcare, starting with the sterile surgical dressings it produced to reduce infections in hospitals. Over the decades, this vision expanded into a global healthcare powerhouse, intricate in its operation yet unified in its mission to improve lives. Johnson & Johnson's business model is built on three core segments: pharmaceuticals, medical devices, and consumer health products. Each segment harnesses the synergy of innovation, research, and a deep understanding of customer needs. The pharmaceutical division, one of its most robust, thrives on producing treatments for various medical conditions, including immunology, oncology, and neuroscience. It is in this domain that cutting-edge research and development efforts translate into high-margin therapies, driving substantial portions of the company's revenue. Beyond pharmaceuticals, the medical devices segment forms a pillar of Johnson & Johnson's operations, offering a spectrum of products essential for surgeries, orthopedics, and vision care. These devices are integral for modern healthcare practices, with their premium positioning contributing significantly to the company’s financial health. Meanwhile, Johnson & Johnson's consumer health division addresses everyday wellness needs, with iconic brands like Band-Aid, Tylenol, and Neutrogena. This segment leverages global brand recognition and trust to generate steady, albeit lower-margin, income streams. Together, these segments compose a diversified revenue platform, buffered against sector-specific downturns and positioning Johnson & Johnson as a formidable entity in global healthcare markets.

JNJ Intrinsic Value
161.11 USD
Undervaluation 6%
Intrinsic Value
Price

See Also

What is Johnson & Johnson's Operating Income?
Operating Income
23.4B USD

Based on the financial report for Mar 30, 2025, Johnson & Johnson's Operating Income amounts to 23.4B USD.

What is Johnson & Johnson's Operating Income growth rate?
Operating Income CAGR 10Y
1%

Over the last year, the Operating Income growth was -4%. The average annual Operating Income growth rates for Johnson & Johnson have been 2% over the past three years , 4% over the past five years , and 1% over the past ten years .

Back to Top